Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 58 articles:
HTML format
Text format



Single Articles


    October 2018
  1. WU G, Cao L, Zhu J, Tan Z, et al
    Loss of RBMS3 Confers Platinum-resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/beta-catenin/CBP signaling.
    Clin Cancer Res. 2018 Oct 2. pii: 1078-0432.CCR-18-2554.
    PubMed     Text format     Abstract available


    September 2018
  2. MATUSZEWSKA K, Santry LA, Van Vloten JP, Au Yeung A, et al
    Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in Advanced Stage Ovarian Cancer.
    Clin Cancer Res. 2018 Sep 11. pii: 1078-0432.CCR-18-0220.
    PubMed     Text format     Abstract available


    July 2018
  3. TOKER A, Nguyen LT, Stone SC, Yang C, et al
    Regulatory T cells in ovarian cancer are characterized by a highly activated phenotype distinct from that in melanoma.
    Clin Cancer Res. 2018 Jul 31. pii: 1078-0432.CCR-18-0554.
    PubMed     Text format     Abstract available


  4. MCNEISH IA
    Neoantigens in ovarian cancer: embarrassment of riches or needles in a haystack?
    Clin Cancer Res. 2018 Jul 6. pii: 1078-0432.CCR-18-1731.
    PubMed     Text format     Abstract available


  5. BLYUSS O, Burnell M, Ryan A, Gentry-Maharaj A, et al
    Comparison of longitudinal CA125 algorithms as a first line screen for ovarian cancer in the general population.
    Clin Cancer Res. 2018 Jul 3. pii: 1078-0432.CCR-18-0208.
    PubMed     Text format     Abstract available


  6. YANG H, Mao W, Rodriguez-Aguayo C, Mangala LS, et al
    Paclitaxel Sensitivity of Ovarian Cancer can be enhanced by knocking down Pairs of Kinases that regulate MAP4 Phosphorylation and Microtubule Stability.
    Clin Cancer Res. 2018 Jul 3. pii: 1078-0432.CCR-18-0504.
    PubMed     Text format     Abstract available


    June 2018
  7. SIMPKINS F, Jang K, Yoon H, Hew K, et al
    Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells.
    Clin Cancer Res. 2018 Jun 29. pii: 1078-0432.CCR-17-3697.
    PubMed     Text format     Abstract available


  8. KONSTANTINOPOULOS PA, Matulonis UA
    PARP inhibitors in ovarian cancer: a trailblazing and transformative journey.
    Clin Cancer Res. 2018 Jun 5. pii: 1078-0432.CCR-18-1314.
    PubMed     Text format     Abstract available


  9. TUMIATI M, Hietanen S, Hynninen J, Pietila E, et al
    A functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients.
    Clin Cancer Res. 2018 Jun 1. pii: 1078-0432.CCR-17-3770.
    PubMed     Text format     Abstract available


    May 2018
  10. GRISHAM R, Moore KN, Gordon MS, Harb W, et al
    Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.
    Clin Cancer Res. 2018 May 29. pii: 1078-0432.CCR-18-0494.
    PubMed     Text format     Abstract available


  11. UUSI-KERTTULA H, Davies JA, Thompson J, Wongthida P, et al
    Ad5NULL-A20 - a tropism-modified, alphavbeta6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies.
    Clin Cancer Res. 2018 May 24. pii: 1078-0432.CCR-18-1089.
    PubMed     Text format     Abstract available


  12. MATSUDA T, Leisegang M, Park JH, Ren L, et al
    Induction of Neoantigen-specific Cytotoxic T Cells and Construction of T-cell Receptor-engineered T cells for Ovarian Cancer.
    Clin Cancer Res. 2018 May 2. pii: 1078-0432.CCR-18-0142.
    PubMed     Text format     Abstract available


    April 2018
  13. DI LJ, Hao D, Liu J, Chen M, et al
    Immunogenomic analyses of advanced serous ovarian cancer reveal immune score is a strong prognostic factor and an indicator of chemo-sensitivity.
    Clin Cancer Res. 2018 Apr 16. pii: 1078-0432.CCR-17-3862.
    PubMed     Text format     Abstract available


  14. BELUR NAGARAJ A, Kovalenko O, Avelar RA, Joseph P, et al
    Mitotic Exit dysfunction through the deregulation of APC/C characterizes cisplatin resistant state in epithelial ovarian cancer.
    Clin Cancer Res. 2018 Apr 13. pii: 1078-0432.CCR-17-2885.
    PubMed     Text format     Abstract available


  15. ISON G, Howie LJ, Amiri-Kordestani L, Zhang L, et al
    FDA Approval Summary: Niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy.
    Clin Cancer Res. 2018 Apr 12. pii: 1078-0432.CCR-18-0042.
    PubMed     Text format     Abstract available


    March 2018
  16. KALLI KR, Block MS, Kasi PM, Erskine CL, et al
    Folate Receptor Alpha Peptide Vaccine generates immunity in Breast and Ovarian Cancer Patients.
    Clin Cancer Res. 2018 Mar 15. pii: 1078-0432.CCR-17-2499.
    PubMed     Text format     Abstract available


  17. MATEI D, Ghamande S, Roman LD, Alvarez Secord A, et al
    A Phase 1 Clinical Trial of Guadecitabine and Carboplatin In Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic And Pharmacodynamic Analyses.
    Clin Cancer Res. 2018 Mar 2. pii: 1078-0432.CCR-17-3055.
    PubMed     Text format     Abstract available


    February 2018
  18. HUANG YF, Wu YH, Cheng WF, Peng SL, et al
    Vitamin D-Binding Protein Enhances Epithelial Ovarian Cancer Progression by Regulating the Insulin-like Growth Factor-1/Akt Pathway and Vitamin D Receptor Transcription.
    Clin Cancer Res. 2018 Feb 23. pii: 1078-0432.CCR-17-2943.
    PubMed     Text format     Abstract available


    January 2018
  19. BELLONE S, Buza N, Choi J, Zammataro L, et al
    Exceptional response to pembrolizumab in a metastatic, chemotherapy/radiation resistant ovarian cancer patient harboring a CD274/PD-L1-genetic rearrangement.
    Clin Cancer Res. 2018 Jan 19. pii: 1078-0432.CCR-17-1805.
    PubMed     Text format     Abstract available


  20. HARDWICK NR, Frankel P, Ruel C, Kilpatrick J, et al
    p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-2709.
    PubMed     Text format     Abstract available


    December 2017
  21. TUCKER DW, Getchell CR, McCarthy ET, Ohman AW, et al
    Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
    Clin Cancer Res. 2017 Dec 20. pii: 1078-0432.CCR-17-1958.
    PubMed     Text format     Abstract available


    November 2017
  22. PENG G, Mills GB
    Surviving ovarian cancer: an affair between defective DNA repair and RB1.
    Clin Cancer Res. 2017 Nov 30. pii: 1078-0432.CCR-17-3022.
    PubMed     Text format     Abstract available


    October 2017
  23. LABIDI-GALY SI, Olivier T, Rodrigues M, Ferraioli D, et al
    Location of mutation in BRCA2 gene and survival in patients with ovarian cancer.
    Clin Cancer Res. 2017 Oct 30. pii: clincanres.2136.2017.
    PubMed     Text format     Abstract available


  24. GARSED DW, Alsop K, Fereday S, Emmanuel C, et al
    Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.1621.2017.
    PubMed     Text format     Abstract available


  25. KREUZINGER C, Geroldinger A, Smeets D, Braicu EI, et al
    A complex network of tumor microenvironment in human high grade serous ovarian cancer.
    Clin Cancer Res. 2017 Oct 2. pii: clincanres.1159.2017.
    PubMed     Text format     Abstract available


    September 2017
  26. COOKE SL, Ennis D, Evers L, Dowson S, et al
    The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma.
    Clin Cancer Res. 2017 Sep 27. pii: clincanres.1789.2017.
    PubMed     Text format     Abstract available


  27. HAO D, Li J, Jia S, Meng Y, et al
    Integrated analysis reveals tubal and ovarian originated serous ovarian cancer and predicts differential therapeutic responses.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0638.2017.
    PubMed     Text format     Abstract available


    August 2017
  28. RAGHAVAN S, Mehta P, Ward MW, Bregenzer ME, et al
    Personalized Medicine Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
    Clin Cancer Res. 2017 Aug 16. pii: clincanres.0133.2017.
    PubMed     Text format     Abstract available


  29. LIU J, Agopiantz M, Poupon J, Wu Z, et al
    Neurotensin receptor 1 antagonist SR48692 improves response to carboplatin by enhancing apoptosis and inhibiting drug efflux in ovarian cancer.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0861.2017.
    PubMed     Text format     Abstract available


  30. CORNELISON R, Dobbin ZC, Katre AA, Jeong DH, et al
    TARGETING RNA-POLYMERASE I IN BOTH CHEMOSENSITIVE AND CHEMORESISTANT POPULATIONS IN EPITHELIAL OVARIAN CANCER.
    Clin Cancer Res. 2017 Aug 4. pii: clincanres.0282.2017.
    PubMed     Text format     Abstract available


  31. WEIGELT B, Comino-Mendez I, de Bruijn I, Tian L, et al
    Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
    Clin Cancer Res. 2017 Aug 1. pii: clincanres.0544.2017.
    PubMed     Text format     Abstract available


    July 2017
  32. BALASUBRAMANIAM S, Beaver JA, Horton S, Fernandes LL, et al
    FDA Approval Summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.1337.2017.
    PubMed     Text format     Abstract available


  33. MENDERES G, Bonazzoli E, Bellone S, Black JD, et al
    SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.2862.2016.
    PubMed     Text format     Abstract available


    June 2017
  34. YANG WL, Gentry-Maharaj A, Simmons AR, Ryan A, et al
    Elevation of TP53 Autoantibody Prior to CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
    Clin Cancer Res. 2017 Jun 21. pii: clincanres.0284.2017.
    PubMed     Text format     Abstract available


  35. HU Q, Hisamatsu T, Hammerle M, Cho MS, et al
    Role of platelet-derived Tgfbeta1 in the progression of ovarian cancer.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.3272.2016.
    PubMed     Text format     Abstract available


    March 2017
  36. LEE JM, Peer CJ, Yu M, Amable L, et al
    Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
    Clin Cancer Res. 2017;23:1397-1406.
    PubMed     Text format     Abstract available


  37. WANG C, Armasu SM, Kalli KR, Maurer MJ, et al
    Pooled clustering of high-grade serous ovarian cancer gene expression leads to novel consensus subtypes associated with survival and surgical outcomes.
    Clin Cancer Res. 2017 Mar 9. pii: clincanres.0246.2017.
    PubMed     Text format     Abstract available


  38. KRISTELEIT R, Shapiro GI, Burris HA, Oza AM, et al
    A Phase I-II Study of the Oral Poly(ADP-ribose) Polymerase Inhibitor Rucaparib in Patients with Germline BRCA1/2-mutated Ovarian Carcinoma or Other Solid Tumors.
    Clin Cancer Res. 2017 Mar 6. pii: clincanres.2796.2016.
    PubMed     Text format     Abstract available


  39. APELLANIZ-RUIZ M, Tejero H, Inglada-Perez L, Sanchez-Barroso L, et al
    Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy.
    Clin Cancer Res. 2017;23:1227-1235.
    PubMed     Text format     Abstract available


    February 2017
  40. LHEUREUX S, Lai Z, Dougherty BA, Runswick S, et al
    Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: Clinical and molecular characterization.
    Clin Cancer Res. 2017 Feb 21. pii: clincanres.2615.2016.
    PubMed     Text format     Abstract available


  41. NG C, Zhang Z, Lee SI, Marques HS, et al
    CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: an ACRIN and GOG study.
    Clin Cancer Res. 2017 Feb 7. pii: clincanres.1859.2016.
    PubMed     Text format     Abstract available


  42. KOMMOSS S, Winterhoff B, Oberg A, Konecny GE, et al
    Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes.
    Clin Cancer Res. 2017 Feb 3. pii: clincanres.2196.2016.
    PubMed     Text format     Abstract available


    January 2017
  43. SKATES SJ, Greene MH, Buys SS, Mai PL, et al
    Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2750.2015.
    PubMed     Text format     Abstract available


  44. ANDERSEN CL, Sikora MJ, Boisen MM, Ma T, et al
    Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.1501.2016.
    PubMed     Text format     Abstract available


    December 2016
  45. KIM H, George E, Ragland RL, Rafail S, et al
    Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models.
    Clin Cancer Res. 2016 Dec 19. pii: clincanres.2273.2016.
    PubMed     Text format     Abstract available


  46. CHATTERJEE J, Dai W, Abd Aziz NH, Teo PY, et al
    Clinical use of programmed cell death-1 (PD-1) and its ligand (PD-L1) expression as discriminatory and predictive markers in ovarian cancer.
    Clin Cancer Res. 2016 Dec 16. pii: clincanres.2366.2016.
    PubMed     Text format     Abstract available


    November 2016
  47. VANDERSTICHELE A, Busschaert P, Smeets D, Landolfo C, et al
    Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses.
    Clin Cancer Res. 2016 Nov 14. pii: clincanres.1078.2016.
    PubMed     Text format     Abstract available


  48. MARTINI P, Paracchini L, Caratti G, Mello-Grand M, et al
    lncRNAs as novel indicators of patients' prognosis in stage I epithelial ovarian cancer: a retrospective and multicentric study.
    Clin Cancer Res. 2016 Nov 8. pii: clincanres.1402.2016.
    PubMed     Text format     Abstract available


    October 2016
  49. BACHMAYR-HEYDA A, Aust S, Auer K, Meier SM, et al
    Integrative Systemic and Local Metabolomics with Impact on Survival in High Grade Serous Ovarian Cancer.
    Clin Cancer Res. 2016 Oct 19. pii: clincanres.1647.2016.
    PubMed     Text format     Abstract available


  50. MONK BJ, Facciabene A, Brady WE, Aghajanian C, et al
    Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemo-immunotherapy.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.1453.2016.
    PubMed     Text format     Abstract available


  51. MCCORMICK A, Donoghue P, Dixon M, O'Sullivan R, et al
    Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.0564.2016.
    PubMed     Text format     Abstract available


    September 2016
  52. ZHOU J, Alfraidi A, Zhang S, Santiago-O'Farrill J, et al
    A novel compound ARN-3236 inhibits Salt Inducible Kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.1562.2016.
    PubMed     Text format     Abstract available


  53. FLANAGAN JM, Wilson A, Koo C, Masrour N, et al
    Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in ovarian cancer patients.
    Clin Cancer Res. 2016 Sep 23. pii: clincanres.1754.2016.
    PubMed     Text format     Abstract available


  54. AU-YEUNG G, Lang F, Azar WJ, Mitchell C, et al
    Selective targeting of Cyclin E1 amplified high grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition.
    Clin Cancer Res. 2016 Sep 23. pii: clincanres.0620.2016.
    PubMed     Text format     Abstract available


  55. MARTIGNETTI JA, Chen Y, Camacho C, Silvers TR, et al
    INHIBITION OF THE NUCLEAR EXPORT RECEPTOR XPO1 AS A THERAPEUTIC TARGET FOR PLATINUM RESISTANT OVARIAN CANCER.
    Clin Cancer Res. 2016 Sep 20. pii: clincanres.1333.2016.
    PubMed     Text format     Abstract available


    June 2016
  56. MONTFORT A, Pearce OM, Maniati E, Vincent B, et al
    A strong B cell response is part of the immune landscape in human high-grade serous ovarian metastases.
    Clin Cancer Res. 2016 Jun 27. pii: clincanres.0081.2016.
    PubMed     Text format     Abstract available


  57. BOHM S, Montfort A, Pearce OM, Topping J, et al
    Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.
    Clin Cancer Res. 2016;22:3025-36.
    PubMed     Text format     Abstract available


    July 2015
  58. YANG JY, Werner HM, Li J, Westin SN, et al
    Integrative Protein-Based Prognostic Model for Early Stage Endometrioid Endometrial Cancer.
    Clin Cancer Res. 2015 Jul 29. pii: clincanres.0104.2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: